223Ra

You have access
A Phase 1, Open-Label Study of the Biodistribution, Pharmacokinetics, and Dosimetry of ²²³Ra-Dichloride in Patients with Hormone-Refractory Prostate Cancer and Skeletal Metastases
Sarah J. Chittenden, Cecilia Hindorf, Christopher C. Parker, Valerie J. Lewington, Brenda E. Pratt, Bernadette Johnson and Glenn D. Flux

Journal of Nuclear Medicine September 1, 2015, 56 (9) 1304-1309; DOI: https://doi.org/10.2967/jnumed.115.157123
You have access
Prognostic Factors in Patients Treated with ²²³Ra: The Role of Skeletal Tumor Burden on Baseline ¹⁸F-Fluoride PET/CT in Predicting Overall Survival
Elba C. Etchebehere, John C. Araujo, Patricia S. Fox, Nancy M. Swanston, Homer A. Macapinlac and Eric M. Rohren

Journal of Nuclear Medicine August 1, 2015, 56 (8) 1177-1184; DOI: https://doi.org/10.2967/jnumed.115.158626

Main menu